News - Stealth BioTherapeutics Inc.

BOSTON – March 4, 2019 – Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that

Press release / March 04, 2019

BOSTON – February 14, 2019 – Stealth BioTherapeutics (Stealth), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the

Press release / February 14, 2019

BOSTON – December 10, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track

Press release / December 10, 2018

Barth syndrome is a rare, genetic, mitochondrial disorder causing metabolic abnormalities that can lead to an enlarged and weakened heart (cardiomyopathy), muscle weakness and fatigue (skeletal muscle myopathy), low levels of certain white blood cells

Press release / August 16, 2018

Stealth BioTherapeutics accelerates the development of a new pipeline candidate into Investigational New Drug enabling studies by leveraging Evotec’s INDiGO platform BOSTON – August 14, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical

Press release / August 14, 2018

BOSTON – June 18, 2018 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing a first-in-class platform of novel therapeutic compounds for the treatment of mitochondrial dysfunction, today announced the closing of an aggregate

Press release / June 18, 2018

Infographic / June 11, 2018 A recent study published in Neurology: Genetics documented the complex journey to diagnosis for

Press release / June 11, 2018

BOSTON – April 30, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development

Press release / April 30, 2018

BOSTON – April 9, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products

Press release / April 09, 2018

We are pleased to share that the prestigious peer-reviewed publication Neurology recently publishedPhase 1/2 safety and efficacy data from the MMPOWER trial, which studied elamipretide versus placebo in adults with primary mitochondrial myopathy (PMM).1

Press release / March 29, 2018

Top-line data expected by the end of 2018 BOSTON – March 6, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational therapeutics to treat mitochondrial dysfunction, today announced the completion

Press release / March 06, 2018

BOSTON – December 18, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track

Press release / December 18, 2017

BOSTON – November 27, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track

Press release / November 27, 2017

BOSTON, Nov. 6, 2017 /PRNewswire/ — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation of MMPOWER-3, a Phase 3 study evaluating the efficacy

Press release / November 06, 2017

BOSTON – October 2, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products

Press release / October 02, 2017

BOSTON – August 7, 2017 – Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, announced the appointment of three directors to its Board of Directors: Francis W.

Press release / August 07, 2017

Study will evaluate elamipretide in rare genetic mitochondrial disease characterized by muscle weakness, cardiac abnormalities, recurrent infections and delayed growth BOSTON – July 19, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical

Press release / July 24, 2017

Press Release / June 29, 2017 BOSTON - JUNE 29, 2017- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced results from MMPOWER-2, a Phase 2 continuation

Press release / June 29, 2017

MMPOWER-2 assessed once daily dosing, tolerability and efficacy of elamipretide in patients who completed the MMPOWER clinical trial Company to feature presentation from primary mitochondrial myopathy program BOSTON – June 15, 2017 – Stealth BioTherapeutics

Press release / June 15, 2017

Study results to inform design and appropriate patient population for interventional Phase 3 clinical trial BOSTON – March 2, 2017 – Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial

Press release / May 02, 2017

SBT-20 is the second investigational compound from Stealth’s mitochondrial platform Trial results to inform development plan for targeting mitochondrial dysfunction in neurodegenerative diseases BOSTON – May 2, 2017 – Stealth BioTherapeutics Inc. (Stealth),

Press release / May 02, 2017

Doug Weaver named Chief Medical Officer, Daniel Geffken named interim Chief Financial Officer and Jim Carr promoted to Chief Clinical Development Officer BOSTON – January 19, 2017 – Stealth BioTherapeutics Inc. (Stealth), a clinical-stage biopharmaceutical

Press release / January 19, 2017

BOSTON – November 28, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present

Press release / November 28, 2016

Data support company’s cardiorenal program, including three ongoing heart failure trials Single elamipretide infusion improves kidney microvasculature and function after renal artery angioplasty BOSTON – November 18, 2016 – Stealth BioTherapeutics (Stealth),

Press release / November 18, 2016

Top-line data from study evaluating elamipretide in patients with dry age-related macular degeneration expected mid-year 2017 BOSTON – November 14, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational

Press release / November 14, 2016

BOSTON – November 8, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present

Press release / November 09, 2016

Late-breaking poster presents data from elamipretide clinical trial in chronic kidney disease patients at risk of acute kidney injury BOSTON – November 7, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing

Press release / November 07, 2016

Top-line results anticipated in second half of 2017 BOSTON – October 25, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction associated with common diseases

Press release / October 25, 2016

Trial evaluating treatment with investigational drug, elamipretide, demonstrated improved mitochondrial function by increasing energy production after single treatment BOSTON – September 19, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical

Press release / September 19, 2016

Study will evaluate the long-term safety, tolerability and efficacy of elamipretide in patients who completed the Phase 2 MMPOWER study BOSTON – September 12, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing

Press release / September 12, 2016

BOSTON – September 6, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Stealth Chief Executive Officer Reenie McCarthy will participate

Press release / September 06, 2016

Trials to evaluate potential treatment option for heart failure patients with either reduced or preserved ejection fraction BOSTON – June 27, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational

Press release / June 27, 2016

Positive Phase 2 data in rare disease trial lead to extension study and planning for Phase 3 BOSTON – June 17, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial

Press release / June 17, 2016

On May 23rd, Brian Stauffer, M.D., cardiologist at the University of Colorado, presented new pre-clinical data examining the effects of elamipretide in human heart cells at Heart Failure 2016 in Florence, Italy. The heart’s reduced ability to relax and

Press release / June 10, 2016

Trial evaluating treatment with elamipretide in rare disease meets efficacy and safety endpoints Data to be presented at Mitochondrial Medicine 2016 on Friday, June 17 at 8:10 a.m. PT BOSTON – June 6, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage

Press release / June 06, 2016

Trial augments ongoing clinical development program for rare genetic mitochondrial diseases BOSTON – June 01, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial

Press release / June 01, 2016

According to the World Health Organization and United States Adopted Names Council (USAN), a generic, or nonproprietary, name should be simple, informative and unique, and based on pharmacological and/or chemical relationships. In 2014, Stealth BioTherapeutics

Press release / May 05, 2016

Trial results support further study of elamipretide in heart failure BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, announced

Press release / April 03, 2016

Top-line data expected Q3 2016 for mitochondria-targeted treatment for debilitating eye condition BOSTON – March 8, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial

Press release / March 08, 2016

BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the

Press release / March 01, 2016

Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction,

Press release / January 07, 2016

In the May/June cover story of Retina Today, Scott W. Cousins, MD, offers insights into how our investigational mitochondrial targeted drug Ocuvia (MTP-131) may help treat age-related macular degeneration (AMD). AMD accounts for 54% of all blindness in

Press release / September 09, 2015

Corporate Presentation on Wednesday, July 8th, 2015 at 9:30 AM ET BOSTON – July 7, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced its Chief Executive

Press release / July 07, 2015

Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results

Press release / June 25, 2015

Orphan mitochondrial disease program highlighted during annual meeting Boston, MA – June 22, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, provided a development

Press release / June 22, 2015

Presentation will be on Monday, June 1st, 2015 at 10:30 AM ET Boston, MA – May 27, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Travis Wilson,

Press release / May 27, 2015

Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases Boston, MA – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing

Press release / April 27, 2015

Promising heart failure results support strategic focus of Stealth’s cardio-renal program Boston, MA — March 15, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases

Press release / March 15, 2015

Leading Nephrologists Convene to Advance Novel Therapies, Translational Research and Clinical Trials for AKI Boston, MA — February 23, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for

Press release / February 23, 2015

The conferences will take place on Monday, March 2, 2015 in Boston and Tuesday, March 10, 2015 in Miami Boston, MA – February 23, 2015 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment

Press release / February 23, 2015

Trial is one of the first to study Mitochondrial Myopathy, a disorder common to over 270 genetic mitochondrial diseases Boston, MA – February 17, 2015 – Stealth BioTherapeutics (Stealth) today announced the initiation of a clinical study of Bendavia in

Press release / February 17, 2015

Ocuvia shows promise in dry age-related macular degeneration (AMD) studies Boston, MA — February 11, 2015 — Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving

Press release / February 13, 2015

Presentation will be on Wednesday, February 11, 2015 at 2:15pm EST Boston, MA – February 4, 2015 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases

Press release / February 04, 2015

Funding grows to more than $100M Boston, MA — January 9, 2015 — (BUSINESS WIRE) — Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial

Press release / January 09, 2015

Mark Colonnese will lead the Company’s financial and capital markets strategy Boston, MA — January 8, 2015 — (BUSINESS WIRE) — Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing investigational drugs

Press release / January 08, 2015

Presentation will be on Wednesday, December 3, 2014 at 10:50 a.m. EST Newton, MA – November 25, 2014 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed to bringing therapies that target mitochondrial

Press release / November 25, 2014

Researchers reported on recent studies demonstrating Bendavia’s ability to improve cardiac function Boston, MA — June 24, 2013—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular

Press release / June 24, 2013

Positive Data Broadens Bendavia’s Potential for Chronic Heart Failure and Cardioprotection BOSTON, MA, January 22, 2013–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies

Press release / January 22, 2013

Clinical Study Broadens Bendavia’s Potential for Acute and Chronic Kidney Disease Boston, MA — January 16, 2013—(BUSINESS WIRE)—Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for cardiovascular

Press release / January 16, 2013

Doctors reported on studies showing Bendavia’s ability to preserve cardiac function Boston, MA — November 26, 2012—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular researchers

Press release / November 26, 2012

Top researchers presented findings showing Bendavia reduced renal and myocardial injury Boston, MA – November 19, 2012–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies

Press release / November 19, 2012

Colloquium featured the latest innovations in cardioprotection and the most up-to-date research Boston, MA — November 2, 2012 — Stealth Peptides co-sponsored the 2012 Cardioprotection Colloquium held at the University of California at Los Angeles today,

Press release / November 02, 2012

First patient was enrolled in its multinational Phase II clinical study today Boston, MA – June 25, 2012–(BUSINESS WIRE)–Stealth Peptides Incorporated (Stealth), a privately held biopharmaceutical company developing innovative therapies for cardiovascular

Press release / June 25, 2012

Announced the results from three Phase I clinical trials of Bendavia Boston, MA – April 9, 2012–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical

Press release / April 09, 2012

Study findings presented during the American Heart Association’s (AHA) annual meeting Boston, MA — November 28, 2011—(BUSINESS WIRE)— Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies

Press release / November 28, 2011

Bendavia study findings presented during the annual American Society of Nephrology (ASN) meeting Boston, MA – November 15, 2011–(BUSINESS WIRE)–Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial

Press release / November 15, 2011